Filtered By:
Specialty: Biomedical Science
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 116 results found since Jan 2013.
Pre-therapeutic molecular biomarkers of pathological response to neoadjuvant chemotherapy in gastric and esophago-gastric junction adenocarcinoma: A systematic review and meta-analysis
CONCLUSION: Previous studies describe a large number of candidate biomarkers. Our meta-analysis indicated pre-therapeutic serum concentration of CEA >5 ng/mL as a potential and easy-accessible biomarker available for use before initiation of treatment. However, it could be only an additional tool for complex qualification for neoadjuvant therapy.PMID:36944288 | DOI:10.1016/j.advms.2023.02.005
Source: Advances in Medical Sciences - March 21, 2023 Category: Biomedical Science Authors: Kamil Nurczyk Norbert Nowak Rebecca Carlson Tomasz Skoczylas Grzegorz Wallner Source Type: research
Protocol: The role of defunctioning stoma prior to neoadjuvant therapy for locally advanced colonic and rectal cancer-A systematic review
by Mina Mesri, Louise Hitchman, Marina Yiaesemidou, Aaron Quyn, David Jayne, Ian Chetter
Defunctioning stomas (ileostomy and colostomy) may be used prior to commencement of neoadjuvant therapy in patients with locally advanced colon or rectal cancer, in order to prevent clinical large bowel obstruction caused by radiotherapy associated oedema or progression of disease in patients who are not obstructed. However, the exact rate of clinical obstruction in patients undergoing neoadjuvant therapy who do not receive a defunctioning stoma is not known. Furthermore, it is not clear which factors predispose patients to developing...
Source: PLoS One - September 22, 2022 Category: Biomedical Science Authors: Mina Mesri Source Type: research
Commentary on: SMARCB1 as a novel diagnostic and prognostic biomarker for osteosarcoma
Biosci Rep. 2022 May 18:BSR20220040. doi: 10.1042/BSR20220040. Online ahead of print.ABSTRACTIn the last couple of decades, biomarkers have been on the rise for diagnostic and predictive value. There has been a rush to identify new markers using new technologies and drug repurposing approaches. SMARCB1 acronym arises from the SWI/SNF (SWItch/Sucrose Non-Fermentable) related Matrix-associated Actin-dependent Regulator of Chromatin subfamily B member 1 (SMARCB1). It is a molecule, whose role is associated with the sucrose metabolism. SMARCB1 is also called INI1 (Integrase Interactor 1). The molecule was discovered in the mid...
Source: Bioscience Reports - May 18, 2022 Category: Biomedical Science Authors: Consolato Sergi Source Type: research
X-Box Binding Protein 1 (XBP1): A Potential Role in Chemotherapy Response, Clinical Pathologic Features, Non-Inflamed Tumour Microenvironment for Breast Cancer
Biosci Rep. 2022 May 11:BSR20220225. doi: 10.1042/BSR20220225. Online ahead of print.ABSTRACTX-box binding protein 1 (XBP1) is mainly expressed in breast cancer (BC) in human cancers. Its tumorigenesis and favourable prognosis are contradictory, and its essential role in chemotherapeutic response and immunosuppression is unknown in BC. The study firstly identified XBP1 who received neoadjuvant chemotherapy (NAC) from GSE25055 and GSE24460. Associations between XBP1 expression and clinicopathological characteristics was investigated using Oncomine, TCGA, UALCAN, and bc-GenExMiner. The prognostic value of XBP1 was assessed u...
Source: Bioscience Reports - May 11, 2022 Category: Biomedical Science Authors: Zhipeng Zhu Hongliang Zhan Anran Sun Heqing Huang Baisheng Chen Fuxing Zhang Source Type: research
SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
CONCLUSION: To our knowledge, this study is the first to analyze SMARCB1 expression in osteosarcoma. SMARCB1 may serve as a novel diagnostic and prognostic biomarker in osteosarcoma.PMID:34984436 | DOI:10.1042/BSR20212446
Source: Bioscience Reports - January 5, 2022 Category: Biomedical Science Authors: Tao Guo Ran Wei Dylan C Dean Francis Hornicek Zhenfeng Duan Source Type: research
Surgery for cervical cancer: consensus & amp; controversies
Indian J Med Res. 2021 Dec 2. doi: 10.4103/ijmr.IJMR_4240_20. Online ahead of print.ABSTRACTSurgery plays an important role in the management of early-stage cervical cancer. Type III radical hysterectomy with bilateral pelvic lymph node dissection using open route is the standard surgical procedure. There is level I evidence against the use of laparoscopic/robotic approach for radical hysterectomy for cervical cancer. Emerging data support the use of sentinel lymph node biopsy and nerve sparing radical hysterectomy in carefully selected patients with early-stage disease. In locally advanced cervical cancer patients, the us...
Source: The Indian Journal of Medical Research - December 2, 2021 Category: Biomedical Science Authors: Pabashi Poddar Amita Maheshwari Source Type: research
